Skip to main content

Mireia Resina Salles

Institutions of which they are part

Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Mireia Resina Salles

Institutions of which they are part

Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Estudio PROBiMS - Efecto de la administración de un probiótico como tratamiento complementario en la esclerósis múltiple: un ensayo clinico aleatorizado, doble ciego y controlado con placebo

IP: Carmen Espejo Ruiz
Collaborators: Carlos Nos Llopis, Herena Eixarch Ahufinger, Mireia Resina Salles, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 227500
Reference: PI24/01122
Duration: 01/01/2025 - 31/12/2027

SGR-Cat 2021: Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Carlos Nos Llopis, Sunny Malhotra Sareen, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Related news

Her nomination means that she will represent UPF in the national competition held annually.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

Related professionals

Cristian Ariel González Cabrera

Cristian Ariel González Cabrera

Postdoctoral researcher
Neurodegenerative Diseases
Read more
Sergi Martí Beltran

Sergi Martí Beltran

Pneumology
Read more
Eva María Pastor Arroyo

Eva María Pastor Arroyo

Research technician
Kidney Physiopathology
Read more
Miriam  Moratal  Cloquell

Miriam Moratal Cloquell

General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.